abatacept
Abatacept shortages ‘resolved’
Pharmacies can expect to have improved access to stocks of Bristol-Myers Squibb’s Orencia (abatacept) 125mg/mL ClickJect autoinjector for subcutaneous injection and prefilled syringe products Following months of supply issues, the …
TGA issues SSSI for abatacept
Pharmacists authorised to substitute Orencia 125mg/mL products to deal with shortages The Therapeutic Goods Administration (TGA) has issued a Serious Scarcity Substitution Instrument (SSSI) in response to shortages of both …
Abatacept shortage hits earlier than forecast
Pharmacists urged to advise patients with prescriptions for Orencia (abatacept) to speak to their specialists as shortages hit Bristol-Myers Squibb Australia (BMS) has advised the Therapeutic Goods Administration (TGA) that …
Supply ‘constrained’ but improving
Substitution instrument extended for abatacept, while others end The Serious Scarcity Substitution Instrument (SSSI) for abatacept (Orencia), originally set to expire on 30 April, has been extended until 30 June. …
Shortage warning
TGA issues warning over ongoing shortages of an arthritis treatment The Therapeutic Goods Administration today (23 February) issued a warning that Bristol-Myers Squibb Australia Pty Ltd had notified them of …
A new substitution
Abatacept added to list of pharmacist-substitutable medicines due to scarcity From today (9 Feb) until 30 April 2022, community pharmacists can interchangeably substitute abatacept syringe (Orencia) and abatacept autoinjector (Orencia …